Allegis Investment Advisors LLC decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 49.0% during the 4th quarter, HoldingsChannel reports. The firm owned 4,271 shares of the biopharmaceutical company’s stock after selling 4,111 shares during the quarter. Allegis Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $262,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Advisor Partners LLC increased its holdings in shares of Bristol-Myers Squibb by 6.9% in the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock valued at $2,356,000 after buying an additional 2,382 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after buying an additional 8,813 shares in the last quarter. Israel Discount Bank of New York increased its holdings in shares of Bristol-Myers Squibb by 31.8% in the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock valued at $586,000 after buying an additional 2,540 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Bristol-Myers Squibb by 0.7% in the third quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after buying an additional 5,451 shares in the last quarter. Finally, Aperio Group LLC increased its holdings in shares of Bristol-Myers Squibb by 12.7% in the third quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock valued at $54,463,000 after buying an additional 96,561 shares in the last quarter. 70.57% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (BMY) opened at $67.92 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05. The stock has a market cap of $112,830.00, a price-to-earnings ratio of 28.78, a price-to-earnings-growth ratio of 2.05 and a beta of 0.98.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.36%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 67.80%.
In related news, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction dated Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.
BMY has been the topic of several research reports. Jefferies Group set a $72.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, February 26th. Bank of America upped their price target on Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a report on Monday, March 5th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a report on Thursday, February 8th. Finally, BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $66.30.
ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Position Reduced by Allegis Investment Advisors LLC” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3254543/bristol-myers-squibb-co-bmy-position-reduced-by-allegis-investment-advisors-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.